Implications of Oral Therapy in Metastatic Breast Cancer: Considerations for Delivery Networks

A recent stakeholder interchange convened by the Institute for Value-Based Medicine and The American Journal of Managed Care^® brought together thought leaders in both the clinical and managed care communities to discuss oral therapeutics in the management of metastatic breast cancer (mBC). Participants discussed the shift of oncology treatments to oral agents, specifically in mBC; strategies for successful uptake of oral therapies, including the impact of coronavirus disease 2019 (COVID-19); and the incorporation of oral therapy for mBC into a value-based accountable payment model. This article is a summary of key points from the discussion with Bruce Feinberg, DO, vice president and chief medical officer at Cardinal Health Specialty Solutions in Atlanta, Georgia.

Download PDF